Yoshimasa Kosaka

Dr. Yoshimasa Kosaka

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2015 in Supportive Care in Cancer
Verified
Journal Article
Open access
PDF file
YKYoshimasa Kosaka
Yoshimasa Kosaka
YRYoshiaki Rai
Yoshiaki Rai
NMNorikazu Masuda
Norikazu Masuda
TTToshimi Takano
Toshimi Takano
TSToshiaki Saeki
Toshiaki Saeki
KTKazuo Tamura
Kazuo Tamura
Pegfilgrastim is a pegylated form of filgrastim, a recombinant protein of granulocyte colony-stimulating factor, that is used to reduce the risk of febrile neutropenia (FN). Here, we report the results of a phase III trial of pegfilgrastim in breast cancer patients receiving docetaxel and cyclophosphamide (TC) chemotherapy.

1 April 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
HHHiroki Harada
Hiroki Harada
KHKei Hosoda
Kei Hosoda
HMHiromitsu Moriya
Hiromitsu Moriya
HMHiroaki Mieno
Hiroaki Mieno
AEAkira Ema
Akira Ema
Keishi YamashitaKeishi Yamashita
Keishi Yamashita
There have been few available prognostic biomarkers in gastric cancer. We rigorously assessed the clinical relevance of promoter DNA methylation of Cysteine dioxygenase type 1 (CDO1) gene, a cancer-specific aberration, in human gastric cancer. Quantitative CDO1 methylation value (TaqMeth V) was initially calculated in 138 gastric cancer patients operated in 2005, and its clinical significance was elucidated. As a subsequent expanded set, 154 gastric cancer patients with pathological stage (pStage) II / III with no postoperative therapy were validated between 2000 and 2010. (1) Median TaqMeth V of CDO1 gene methylation of gastric cancer was 25.6, ranging from 0 to 120.9. As pStage progressed, CDO1 TaqMeth V became higher (p < 0.0001). (2) The optimal cut-off value was determined to be 32.6; gastric cancer patients with high CDO1 gene methylation showed a significantly worse prognosis than those with low CDO1 gene methylation (p < 0.0001). (3) A multivariate cox proportional hazards model identified high CDO1 gene methylation (p = 0.033) as an independent prognostic factor. (4) The results were recapitulated in the expanded set in pStage III, where high CDO1 gene methylation group had a significantly worse prognosis than low CDO1 gene methylation group (p = 0.0065). Hematogenous metastasis was unique in pStage III with high CDO1 gene methylation (p = 0.0075). (5) Anchorage independent growth was reduced in several gastric cancer cell lines due to forced expression of the CDO1 gene, suggesting that abnormal CDO1 gene expression may represent distant metastatic ability. Promoter DNA hypermethylation of CDO1 gene was rigorously validated as an important prognostic biomarker in primary gastric cancer with specific stage.


13 September 2018 in Molecular and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYoshimasa Kosaka
Yoshimasa Kosaka
NMNaoko Minatani
Naoko Minatani
YTYoko Tanaka
Yoko Tanaka
ASAkiko Shida
Akiko Shida
MKMariko Kikuchi
Mariko Kikuchi
MWMasahiko Watanabe
Masahiko Watanabe
In recent years, treatment options for breast cancer have increased, and prognosis has improved since the 1990s. The present study examined the prognosis for recurrence of breast cancer between 2006 and 2009, in comparison with the results of past treatments, and sought to guide future treatment strategies by elucidating present prognostic factors. A total of 662 patients with breast cancer stage 0‑III who underwent surgery at Kitasato University Hospital between January 2006 and March 2009 were included. Cases were classified into four subtypes, based on the presence or absence of hormone receptors and human epidermal growth factor receptor 2 (HER2). Factors associated with recurrence and prognosis were then examined. The 5‑year recurrence‑free survival (RFS) was 94.9% and the 5‑year disease‑specific survival (DSS) was 98.4%. Factors related to RFS were pathological lymph node (pN) positive [hazard ratio (HR)=2.85, P=0.001], clinical lymph node (cN) positive (HR=2.28, P<0.01), and hormone receptor negative (HR=1.83, P<0.05). Factors associated with DSS were cN positive (HR=4.55, P<0.01), pN positive (HR=3.40, P<0.05), higher preoperative serum carcinoembryonic antigen (CEA) (HR=3.04, P<0.05), and hormone receptor negative (HR=2.32, P<0.05). In the hormone receptor positive HER2 negative, cN‑positive/pN‑positive breast cancer group, RFS and DSS were poorer compared with the other groups. In this group, preoperative high CEA level was a poor prognostic factor. The prognosis for hormone receptor positive HER2‑negative breast cancer has improved significantly since the 1990s. On the other hand, the prognosis for cN‑positive/pN‑positive breast cancer was poor. Pre‑treatment serum CEA positive cases exhibited a particularly poor prognosis.

31 October 2012 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
YKYoshimasa Kosaka
Yoshimasa Kosaka
AKAkemi Kataoka
Akemi Kataoka
HYHiroshi Yamaguchi
Hiroshi Yamaguchi
HUHiroaki Ueo
Hiroaki Ueo
SASayuri Akiyoshi
Sayuri Akiyoshi
MMMasaki Mori
Masaki Mori
Introduction: Identification of useful markers associated with poor prognosis in breast cancer patients is critically needed. We previously showed that expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful to predict distant metastasis in gastric cancer patients. However, expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood of breast cancer patients has not yet been studied. Methods: Real-time reverse transcriptase-PCR was used to analyze vascular endothelial growth factor receptor-1 mRNA expression status with respect to various clinical parameters in 515 patients with breast cancer and 25 controls. Results: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood was higher in breast cancer patients than in controls. Increased vascular endothelial growth factor receptor-1 mRNA expression was associated with large tumor size, lymph node metastasis and clinical stage. Patients with high vascular endothelial growth factor receptor-1 mRNA expression also experienced a poorer survival rate than those with low expression levels, including those patients with triple-negative type and luminal-HER2(-) type disease. Conclusions: Expression of vascular endothelial growth factor receptor-1 mRNA in peripheral blood may be useful for prediction of poor prognosis in breast cancer, especially in patients with triple-negative type and luminal-HER2(-) type disease.

1 November 2019 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
MKMariko Kikuchi
Mariko Kikuchi
YTYoko Tanaka
Yoko Tanaka
MYMitsuo Yokota
Mitsuo Yokota
HNHiroshi Nishimiya
Hiroshi Nishimiya
HKHiroshi Katoh
Hiroshi Katoh
YKYoshimasa Kosaka
Yoshimasa Kosaka
Palbociclib is a first‑in‑class potent oral inhibitor of cyclin‑dependent kinase (CDK)4/6 that was approved in the USA in 2015 and in Japan in 2017. Next‑generation abemaciclib was approved in the USA and Japan in 2018. The use of palbociclib results in a high frequency of bone marrow suppression, whereas abemaciclib induces a low frequency of bone marrow suppression, but a high incidence of diarrhea. However, the most appropriate uses for these CDK4/6 inhibitors remain unclear. In this study, we analyzed the efficacy and side‑effects associated with the use of palbociclib at our hospital and examined the suitability of palbociclib or abemaciclib. Among 35 patients who used palbociclib at our hospital from December, 2017 to December, 2018, the mean age was 39‑83 years. The patients receiving treatment with palbociclib with a combination of drugs included 20 patients (57%) receiving fulvestrant, 8 patients (23%) receiving letrozole, and 7 patients (20%) receiving fulvestrant + LH‑RH (leuprorelin). Fourteen patients (40%) had a history of receiving chemotherapy, and 21 patients (60%) had no history of receiving chemotherapy. The number of prior treatment regimens was 0‑11 (mean, 2.9). The initial dose of palbociclib was 125 mg for 29 patients (83%) and 100 mg for 6 patients (17%). Partial response, stable disease and progressive disease were achieved in 6 (17%), 19 cases (54%) and 10 cases (29%), respectively. Leukocytopenia was observed in 24 cases, neutropenia was observed in 26 cases, anemia was observed in 13 cases, thrombocytopenia was observed in 15 cases, fatigue was observed in 3 cases and itchy skin was observed in 1 case. When the number of neutrophils prior to palbociclib introduction was <3,000, neutropenia of grade 3 or higher was observed in all cases following palbociclib introduction. Thus, in order to avoid grade 3 or higher neutropenia and to maintain relative dose intensity, abemaciclib treatment may be considered for cases with neutrophils of <3,000 prior to the introduction of a CDK4/6 inhibitor.